Trial Profile
Open-label, Phase II Study of Trastuzumab Emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib: HERACLES RESCUE. (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification - REchallenge With her2 Selective Cytotoxic Uptake of Emtansine)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Adenocarcinoma; Colon cancer; Rectal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms HERACLES RESCUE; RESCUE
- 13 Sep 2022 Status changed from recruiting to discontinued as per the results presented at the 47th European Society for Medical Oncology Congress.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress.
- 21 Sep 2020 Results (n=92) of an analysis from HERACLES clinical program and other clinical trials assessing prevalence, timing of onset, and management of CNS recurrences in largest cohort of Colorectal cancer treated with anti-HER2 therapies at Niguarda Cancer Center presented at the 45th European Society for Medical Oncology Congress